Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine

Vaccine

Volumn 17, Issue 17, 1999, Pages 2192-2203

  Brunel, F ^a   Darbouret, A ^a   Ronco, J ^a  

^a Research Department   (France)

Author keywords

Adjuvant; Hepatitis B vaccine; Unresponsiveness

Indexed keywords

3BETA [N (N',N' DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL; ALUMINUM HYDROXIDE; CATION; CYTOKINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; LIPID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; HEPATITIS B; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; CHO CELLS; CHOLESTEROL; CRICETINAE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; TH1 CELLS; TH2 CELLS;

EID: 0033597327     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00492-7     Document Type: Article

References (44)

1. Gupta R.K., Siber G.R. Adjuvants for humans vaccines: current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
2. Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunol. Today. 14:1993;281-284.
3. Sedlik C. Th1 and Th2 subsets of T lymphocytes: characteristics, physiological role and regulation. Bull. Inst. Pasteur. 94:1996;173-200.
4. Valensi J.-P.M., Carlson J.R., Nest G.A.V. Systemic cytokine profiles in BALB/c mice immunized with trivalent Influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J. Immunol. 153:1994;4029-4039.
5. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R. Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:1986;2348-2357.
6. Cherwinski H.M., Shumacher J.H., Brown K.D., Mosmann T.R. Two types of mouse helper T-cell clone. III. Further differences in lymphokines synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionnaly monospecific bioassays and monoclonal antibodies. J. Exp. Med. 166:1987;1229-1244.
7. Coffman R.L., Seymour B.W.P., Lebman D.A., Hiraki D.D., Christiansen J.A., Shrader B., Cherwinski J.A., Savelkoul H.F.J., Finkelman F.D., Bond M.W., Mosmann T.R. The role of helper T-cell products in mouse B-cell differentiation and isotype regulation. Immunol. Rev. 102:1988;5-28.
8. Reiner S.L., Seder R.A. T-helper cell differentiation in immune response. Curr. Opin. Immunol. 7:1995;360-366.
9. Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol. Today. 12(8):1991;256-257.
10. Wierenga E.A., Snoek M., De groot C., Chretien I., Bos J.D., Jansen H.M., Kapsenberg M. Evidence for compartmentalisation of functional subsets of CD4+ T-lymphocytes in atopic patients. J. Immunol. 144:1990;4651-4656.
11. Salgame P., Abrams J.S., Clayberger C., Goldstein H., Convit J., Modlin R.L., Bloom B.R. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T-cell clones. Science. 254:1991;277-279.
12. Cher D.J., Mosmann T.R. Two types of murine helper T-cell clones. II. Delayed-type hypersensitivity is mediated by Th1 clones. J. Immunol. 138:1987;3688-3694.
13. Mosmann T.R., Sad S. The expanding universe of T-cells subsets: Th1, Th2 and more. Immunol. Today. 17:1996;138-146.
14. Mahon B.P., Katrak K., Nomoto A., Macadam A.J., Minor P.D., Milles K.H.G. Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor. J. Exp. Med. 181:1995;1285-1292.
15. Coutelier J.P., Van der Logt J.T.M., Heessen F.W.A., Vink A., Van Snick J. Virally induced modulation of murine IgG antibody subclasses. J. Exp. Med. 168:1988;2373-2378.
16. Gupta R.K., Rost B.E., Relyveld E., Siber G.R. Adjuvant properties of aluminium and calcium compounds In: Powell M.F., Newman M.J., editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Publishing Corporation, 1995. p. 229-48.
17. Yang X., Hayglass K.T. Allergen-dependent induction of interleukin-4 synthesis in vivo. Immunology. 78:1993;74-79.
18. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Kanta Gupta C. Adjuvants: a balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.
19. Diminsky D., Reimann Z.J., Schirmbeck R., Barenholz Y. Structural and functional characterization of liposomal recombinant hepatitis B vaccine. J. Liposome Res. 6:1996;289-304.
20. Geissler M., Tokushige K., Chante C.C., Zurawski V.R. Jr., Wands J.R. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunisation. Gastroenterology. 112:1997;1307-1320.
21. Zannolli R., Morgese G. Hepatitis B vaccine: current issues. An. Pharmacother. 31:1997;1059-1067.
22. Rustgi V.K., Schleupner C.J., Krause D.S. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1 and 6 months in healthy adults. Vaccine. 13:1995;1665-1668.
23. Lei H.Y., Lee S.C., Yu C.K. Distinct regulation of humoral and cellular immunities to hepatitis B surface antigen. Immunology. 71:1990;347-351.
24. Milich D.R. T- and B-cell recognition of hepatitis B viral antigens. Immunol. Today. 9:1988;380-386.
25. Marescot M.R., Budkowska A., Pillot J., Debre P. HLA linked immune response to S and pre-S2 gene products in hepatitis B vaccination. Tissue Antigens. 33:1989;495-500.
26. Deulofeut H., Iglesias A., Mikael N., Bing D.H., Awdeh Z., Yunis J., Marcus-Bagley D., Kruskall M.S., Alper C.A., Yunis E.J. Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals. Mol. Immunol. 30:1993;941-948.
27. Gao X., Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 179:1991;280-285.
28. Hui K.M., Sabapathy T.K., Oei A.A., Singhal A., Huang L. Induction of alloreactive cytotoxic T-lymphocytes by intrasplenic immunization with allogeneic class I major histocompatibility complex DNA and DC-Chol cationic liposomes. J. Liposome Res. 4:1994;1075-1090.
29. Goyal K., Huang L. Gene therapy using DC-Chol liposomes. J. Liposome Res. 5:1995;49-60.
30. Haensler J., Trannoy E., Ronco, J. Patent Application WO 96/14831, 1996.
31. Krugman S., Stevens C. Hepatitis B vaccine. In: S.A. Plotkin, E.A. Mortimer, editors. Vaccines. 2nd ed. Philadelphia: W.B. Saunders Company, 1994. . 419-37.
32. Vento S., Rondanelli E.G., Ranieri S., O'Brien C.J., Williams R., Eddleston A.L. Prospective study of cellular immunity to hepatitis-B-virus antigens from the early incubation phase of acute hepatitis B. Lancet. 2:1987;119-122.
33. Byars N.E., Nakano G., Welch M., Lehman D., Allison A.C. Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine. 9:1991;309-318.
34. Pillot J., Poynard T., Elias A., Maillard J., Lazizi Y., Brancer M., Dubreuil P., Budkowska A., Chaput J.C. Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine. Vaccine. 13:1995;545-548.
35. Chedid M.G., Deulofeut H., Yunis D.E., Lara-Marqueuz M.L., Salazar M., Deulofeut R., Awdeh Z., Alper C.A., Yunis E. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Human Immunol. 58:1997;42-51.
36. De Wit D., Mechelen M.V., Ryelandt M., Figueiredo A.C., Abramowicz D., Goldman M., Bazin H., Urbain J., Leo O. The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T-helper 1 but not type 2 lymphocytes. J. Exp. Med. 175:1992;9-14.
37. Von der Weid T., Langhorne J. Altered response of CD4+ T-cell subsets to Plasmodium chabaudi chabaudi in B-cell deficient mice. Int. Immun. 5:1993;1343-1348.
38. Rossi-Bergmann B., Müller I., Godinho E.B. Th1 and Th2 T-cells subsets are differentially activated by macrophages and B cells in murine leishmaniasis. Infect. Immun. 61:1993;2266-2269.
39. Neurath A.R., Kent S.B.H., Strick N. Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science. 224:1984;392-395.
40. Neurath A.R., Kent S.B., Strick N., Parker K., Courouce A.M., Riottot M.M., Petit M.A., Budkowska A., Girard M., Pillot J. Antibodies to synthetic peptides from the pre-S1 and pre-S2 regions of one subtype of the hepatitis B virus (HBV) envelope protein recognise all HBV subtypes. Mol. Immunol. 24:1987;975-980.
41. Neurath A.R., Kent S.B., Strick N., Parker K. Delineation of contiguous determinants essential for biological functions of the pre-S sequence of the hepatitis B virus envelope protein: its antigenicity, immunogenicity and cell-receptor recognition. Ann. Inst. Pasteur Virol. 139:1988;13-38.
42. Hervas-Stubbs S., Berasian C., Golvano J.J., Lasarte J.J., Prieto I., Sarobe P., Borras-Cuesta F. Overcoming class II-linked nonresponsiveness to hepatitis B vaccine. Vaccine. 12:1994;867-871.
43. Milich D.R., Thornton G.B., Neurath A., Kent S., Michel M., Tiollais P., Chisari F.V. Enhanced immunogenicity of the preS region of hepatitis B surface antigen. Science. 228:1985;1195-1197.
44. Milich D.R., Lachlan A., Chisari F.V., Kent S., Thornton G.B. Immune response to the preS1 region of the hepatitis B surface antigen (HBsAg): a preS1 specific T-cell response can bypass nonresponsiveness to the preS2 and S regions of HBsAg. J. Immunol. 137:1986;315-322.